Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965407 | 0.91 | KMT2A (0.52) | MEN1KMT2ARAB9ATTKAURKA | |
| SCHEMBL3965414 | 0.90 | MAP2K4 (0.57) | TTKAURKAGAAMAP2K4MAP2K7 | |
| SCHEMBL3969942 | 0.88 | MAP2K4 (0.54) | AURKAMAP2K4MAP2K7ALDH1A1 | |
| SCHEMBL3963379 | 0.88 | MAP2K4 (0.56) | MEN1KMT2AAURKAGAAMAP2K4 | |
| SCHEMBL3966208 | 0.88 | MAP2K4 (0.56) | AURKAMAP2K4MAP2K7ALDH1A1 | |
| SCHEMBL3967980 | 0.86 | MAP2K4 (0.62) | MEN1KMT2AMAP2K4MAP2K7 | |
| SCHEMBL3971858 | 0.85 | MAP2K4 (0.56) | AURKAMAP2K4PKMMAP2K7ALDH1A1 | |
| SCHEMBL3973325 | 0.84 | MAP2K4 (0.51) | MEN1KMT2AAURKAMAP2K4PKM | |
| SCHEMBL3966924 | 0.83 | MAP2K4 (0.57) | MEN1KMT2AAURKAMAP2K4MAP2K7 | |
| SCHEMBL3973335 | 0.83 | MAP2K4 (0.56) | AURKAMAP2K4MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K20 | MEN1 2974/4885KMT2A 3163/4885RAB9A 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.